Clinical trials: Oligoprogressive
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT
At the moment there is a lack of data in the setting of oligometastatic PC in particular regarding the interaction between ablative SBRT, ADT and patient's immune system response.
- Trial name
- IOSCAR (NCT04624828)
- Testing
- Radiotherapy, androgen deprivation therapy (ADT), immune evaluation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Clinico Humanitas
Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma…
- Conditions
- Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT05830058
- Testing
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Metastatic Renal Cell Carcinoma, Radiotherapy
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Every year, 12500 primary renal cell carcinoma (RCC) are diagnosed in France. Metastases occur in half of RCC patients. Management of metastatic RCC is based on systemic treatments (targeted therapies/immunotherapy).
- Trial name
- GETUG-StORM-01 (NCT04299646)
- Testing
- Steretactic radiotherapy
- Where
- 30 sites in France
- Volunteers
- 77 people
- Sponsor
- Centre Francois Baclesse
HCC
SBRT in HCC With Oligoprogression on First-line Immunotherapy
HCC is a huge healthcare burden in Hong Kong and is one of the top 5 cancers in terms of incidence and mortality in Hong Kong. Patients with advanced HCC are treated with immunotherapy-based as first-line treatment as a standard…
- Trial name
- NCT06434480
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Early Stage Non-Small Cell Lung Cancer
Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer
The first phase of this study was an open label, randomized pilot study. Enrollment for this phase is now complete. The second phase is a single arm phase 1 safety study.
- Trial name
- NCT03546829
- Testing
- Vancomycin, Precision hypofractionated radiation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
NSCLC, EGFR Positive Non-small Cell Lung Cancer
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study
Study Objectives are: To assess the safety of osimertinib treatment continuation during irradiation therapy for palliation or oligoprogressive disease by assessment of grade 3-5 AEs during and after concomitant osimertinib and…
- Conditions
- NSCLC, EGFR Positive Non-small Cell Lung Cancer, Oligoprogression
- Trial name
- ROSE (NCT05089916)
- Testing
- Osimertinib, Radiotherapy
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- AIO-Studien-gGmbH
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse
- Conditions
- TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV
- Trial name
- NCT03808662
- Testing
- Sterotactic Body Radiotherapy/SBRT, Standard of care
- Where
- 10 sites in United States, Canada
- Volunteers
- 107 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
This phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first started to other places in the body…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Trial name
- NCT06260033
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Cervical Cancer, Gynecologic Cancer
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
OLIGYNE-10 RT is an international registry of adults with gynecologic cancer and a limited number of active sites of cancer spread who receive radiotherapy (RT) to at least one metastatic lesion during routine care.
- Conditions
- Cervical Cancer, Gynecologic Cancer, Endometrial Cancer, Uterine Cancer
- Trial name
- OLIGYNE-10 RT (NCT07883798)
- Testing
- Routine-care metastasis-directed radiotherapy
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Non Small Cell Lung Cancer, Oligoprogressive
Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma
This is a randomized phase II study designed to evaluate the effect of local consolidative radiation therapy (LCT) to all sites of oligoprogressive disease in patients with metastatic non-small cell lung carcinoma who have…
- Trial name
- NCT04485026
- Testing
- Local consolidative radiation therapy, Standard of care radiation therapy
- Sponsor
- Wake Forest University Health Sciences
Low-dose Radiotherapy, Tumor Microenvironment
Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy
The purpose of this phase Ⅱ trial was to investigate the effect of low-dose radiotherapy (LDRT) on the tumor immune microenvironment (TME) in oligometastasis, oligoprogression, and oligopersistence of non-small cell lung cancer…
- Conditions
- Low-dose Radiotherapy, Tumor Microenvironment, Non-Small Cell Lung Cancer
- Trial name
- NCT06331585
- Testing
- low dose radiotherapy
- Where
- China
- Sponsor
- Hetian District People's Hospital
Oligoprogressive Prostate Cancer, Metastatic Prostate Cancer
PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer
PSMA-OLIGO-PRO is a multicenter, ambispective, observational real-world evidence registry of adults with metastatic hormone-sensitive or metastatic castration-resistant prostate cancer who develop a limited number of progressing…
- Trial name
- PSMA-OLIGO-PRO (NCT07691697)
- Testing
- Comprehensive Progression-Directed Radiotherapy
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Stereotactic Body Radiation Therapy (SBRT), Oligometastasis
SMC Radiation Oncology SABR Cohort for Oligometastasis
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1.
- Conditions
- Stereotactic Body Radiation Therapy (SBRT), Oligometastasis, Oligoprogression, ctDNA
- Trial name
- SABR-OMOP (NCT07121335)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Non-small Cell Lung Cancer, Oligoprogressive
A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression
This Phase II randomized study is to explore the efficacy and safety of Furmonertinib combined with radiotherapy for non-small cell lung cancer with oligoprogression after first-line EGFR-TKI therapy.
- Trial name
- NCT04970693
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sun Yat-sen University
NSCLC Stage IV
SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors
The treatment modality with immunotherapy has been the first-line standard treatment for advanced NSCLC. But more than 2/3 patients still develop acquired drug resistance within 5 years of immunotherapy, and more than 1/2…
- Trial name
- NCT05387044
- Testing
- SBRT
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Zhejiang Cancer Hospital
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
This phase II trial tests how well biologically guided radiation therapy (BgRT) and stereotactic body radiation therapy (SBRT) with osimertinib works for the treatment of EGFR positive non-small cell lung carcinoma that has…
- Trial name
- NCT06014827
- Testing
- Biospecimen Collection, Computed Tomography, Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Small Bowel Cancer, Colorectal Cancer
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective.
- Conditions
- Small Bowel Cancer, Colorectal Cancer, Appendiceal Cancer, Biliary Cancer
- Trial name
- LIVELONG (NCT06101277)
- Testing
- Ablative local therapy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, Davis
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
This is the first pilot phase II trial assessing the response of SBRT layered on Darolutamide (BAY1841788) on RPFS and deferring palliative second line systemic therapy in M0CRPC with oligoprogression.
- Trial name
- NCT04070209
- Testing
- Darolutamide (BAY1841788), SBRT
- Where
- 11 sites in Canada
- Volunteers
- 66 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Non-small Cell Lung Cancer, Oligoprogressive
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective.
- Conditions
- Non-small Cell Lung Cancer, Oligoprogressive, Small-cell Lung Cancer
- Trial name
- OBLITERATE (NCT06103682)
- Testing
- Ablative local therapy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, Davis
HCC - Hepatocellular Carcinoma, Radiotherapy
Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
Immune checkpoint inhibitors (ICIs) have significantly improved the survival outcomes of HCC patients. However, a considerable proportion of patients eventually experience disease progression due to the development of resistance.
- Trial name
- NCT06870942
- Testing
- Maintenance first-line treatment plus radiation therapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital